Feb. 14, 2024

Sioux Falls-based SAB Biotherapeutics Inc. has a new CEO.

Samuel Reich, who joined the company in 2021 as executive chairman of the board of directors, takes on the top executive role. Co-founder Eddie Sullivan transitions to president and a member of the board, reporting to the board and maintaining leadership of operational, research and development functions.

Reich will remain executive chairman, a role he has held since SAB combined with Big Cypress Acquisition Group, where he served as CEO, chief financial officer and a member of the board. Reich co-founded Biscayne Neurotherapeutics Inc. in 2011 and served as its executive chairman until its sale to Supernus Pharmaceuticals in 2018. He is listed as an inventor on 14 U.S. patents and over 50 worldwide patents.

SAB, which trades on the Nasdaq as SABS, is a clinical-stage biopharmaceutical company with a novel immunotherapy platform. It is developing fully human anti-thymocyte immunoglobulin, or hIgG, for delaying the onset or progression of Type 1 diabetes. The product is known as SAB-142.

“We have spent considerable time and effort to develop the optimal organizational structure best suited to executing our business strategy and progression of our lead product candidate, SAB-142, through milestones toward approval,” Recih said in a statement. “I’ve worked collaboratively for more than two and half years with Eddie, who is an outstanding leader and partner. I look forward to continuing to work closely with him to ensure the success of SAB.”

Sullivan added: “The time is right for us to shift our respective focus as SAB prepares for a year of potential milestones. I am enthusiastic about what comes next for SAB and SAB-142, and what our company’s success could mean for patients.”